Snowden Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-7,047
| Closed | -$580K | – | 1221 |
|
|
2024
Q2 | $580K | Sell |
7,047
-279
| -4% | -$23K | 0.02% | 679 |
|
|
2024
Q1 | $640K | Sell |
7,326
-80
| -1% | -$6.99K | 0.02% | 653 |
|
|
2023
Q4 | $714K | Buy |
7,406
+1,766
| +31% | +$170K | 0.03% | 540 |
|
|
2023
Q3 | $499K | Sell |
5,640
-11
| -0.2% | -$973 | 0.02% | 656 |
|
|
2023
Q2 | $490K | Sell |
5,651
-40
| -0.7% | -$3.47K | 0.02% | 745 |
|
|
2023
Q1 | $553K | Buy |
5,691
+245
| +4% | +$23.8K | 0.02% | 689 |
|
|
2022
Q4 | $564K | Buy |
5,446
+587
| +12% | +$60.7K | 0.02% | 657 |
|
|
2022
Q3 | $411K | Buy |
4,859
+1,782
| +58% | +$151K | 0.02% | 730 |
|
|
2022
Q2 | $254K | Buy |
+3,077
| New | +$254K | 0.01% | 938 |
|
|
2022
Q1 | – | Sell |
-217
| Closed | -$19K | – | 1170 |
|
|
2021
Q4 | $19K | Buy |
+217
| New | +$19K | ﹤0.01% | 1341 |
|